Zymeworks Acquires Theravance Biopharma for $929M, Bolstering COPD Portfolio — Zymeworks Inc.

Event summary

Zymeworks to acquire Theravance Biopharma for $929M in cash, closing expected in H2 2026.
Deal adds YUPELRI® (revefenacin), a nebulized LAMA for COPD maintenance, generating ~$60M annual cash flow.
$350M non-recourse note from OMERS Life Sciences secures the deal, minimizing Zymeworks' net capital at risk.
Zymeworks to receive $100M TRELEGY ELLIPTA® milestone in Q1 2027, offsetting ~50% of cash outlay.
Acquisition includes additional royalty interests, preclinical I&I portfolio, and $2.5B Irish tax attributes.

The big picture

Zymeworks' acquisition of Theravance Biopharma aligns with its strategy of combining partner-driven cash flows with innovative R&D. The deal diversifies Zymeworks' revenue sources and strengthens its position in the biotech sector, leveraging established medicines to fund next-generation therapies. With a focus on long-term value creation, Zymeworks aims to capitalize on the growing demand for COPD treatments while maintaining balance sheet flexibility.

What we're watching

Integration Challenges: How Zymeworks will manage the integration of Theravance Biopharma's assets and align resources with YUPELRI® commercial focus.
Cash Flow Growth: Whether YUPELRI® sales can sustain current growth rates and contribute to Zymeworks' earnings accretion.
Portfolio Optimization: The pace at which Zymeworks externalizes acquired assets, particularly ampreloxetine, to monetize the deal.